BHC
Price
$5.89
Change
-$0.50 (-7.82%)
Updated
Jul 31 closing price
Capitalization
3.86B
90 days until earnings call
ZTS
Price
$145.79
Change
-$3.02 (-2.03%)
Updated
Jul 31 closing price
Capitalization
77.48B
4 days until earnings call
Interact to see
Advertisement

BHC vs ZTS

Header iconBHC vs ZTS Comparison
Open Charts BHC vs ZTSBanner chart's image
Bausch Health Companies
Price$5.89
Change-$0.50 (-7.82%)
Volume$4.96M
Capitalization3.86B
ZOETIS
Price$145.79
Change-$3.02 (-2.03%)
Volume$4.86M
Capitalization77.48B
BHC vs ZTS Comparison Chart in %
Loading...
BHC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BHC vs. ZTS commentary
Aug 01, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BHC is a StrongBuy and ZTS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 01, 2025
Stock price -- (BHC: $5.89 vs. ZTS: $145.79)
Brand notoriety: BHC and ZTS are both notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: BHC: 257% vs. ZTS: 158%
Market capitalization -- BHC: $3.86B vs. ZTS: $77.48B
BHC [@Pharmaceuticals: Other] is valued at $3.86B. ZTS’s [@Pharmaceuticals: Other] market capitalization is $77.48B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.87B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BHC’s FA Score shows that 0 FA rating(s) are green whileZTS’s FA Score has 1 green FA rating(s).

  • BHC’s FA Score: 0 green, 5 red.
  • ZTS’s FA Score: 1 green, 4 red.
According to our system of comparison, ZTS is a better buy in the long-term than BHC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BHC’s TA Score shows that 3 TA indicator(s) are bullish while ZTS’s TA Score has 4 bullish TA indicator(s).

  • BHC’s TA Score: 3 bullish, 5 bearish.
  • ZTS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ZTS is a better buy in the short-term than BHC.

Price Growth

BHC (@Pharmaceuticals: Other) experienced а -13.13% price change this week, while ZTS (@Pharmaceuticals: Other) price change was -4.60% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -1.52%. For the same industry, the average monthly price growth was +6.04%, and the average quarterly price growth was +81.88%.

Reported Earning Dates

BHC is expected to report earnings on Oct 30, 2025.

ZTS is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (-1.52% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ZTS($77.5B) has a higher market cap than BHC($3.86B). ZTS has higher P/E ratio than BHC: ZTS (32.94) vs BHC (13.39). ZTS YTD gains are higher at: -9.645 vs. BHC (-26.923). ZTS has higher annual earnings (EBITDA): 3.67B vs. BHC (2.2B). ZTS has more cash in the bank: 2.04B vs. BHC (947M). ZTS has less debt than BHC: ZTS (6.76B) vs BHC (22.4B). BHC (8.76B) and ZTS (8.54B) have equivalent revenues.
BHCZTSBHC / ZTS
Capitalization3.86B77.5B5%
EBITDA2.2B3.67B60%
Gain YTD-26.923-9.645279%
P/E Ratio13.3932.9441%
Revenue8.76B8.54B102%
Total Cash947M2.04B46%
Total Debt22.4B6.76B332%
FUNDAMENTALS RATINGS
BHC vs ZTS: Fundamental Ratings
BHC
ZTS
OUTLOOK RATING
1..100
7160
VALUATION
overvalued / fair valued / undervalued
1..100
35
Fair valued
54
Fair valued
PROFIT vs RISK RATING
1..100
10087
SMR RATING
1..100
10019
PRICE GROWTH RATING
1..100
5562
P/E GROWTH RATING
1..100
10079
SEASONALITY SCORE
1..100
49n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BHC's Valuation (35) in the Pharmaceuticals Other industry is in the same range as ZTS (54) in the Pharmaceuticals Generic industry. This means that BHC’s stock grew similarly to ZTS’s over the last 12 months.

ZTS's Profit vs Risk Rating (87) in the Pharmaceuticals Generic industry is in the same range as BHC (100) in the Pharmaceuticals Other industry. This means that ZTS’s stock grew similarly to BHC’s over the last 12 months.

ZTS's SMR Rating (19) in the Pharmaceuticals Generic industry is significantly better than the same rating for BHC (100) in the Pharmaceuticals Other industry. This means that ZTS’s stock grew significantly faster than BHC’s over the last 12 months.

BHC's Price Growth Rating (55) in the Pharmaceuticals Other industry is in the same range as ZTS (62) in the Pharmaceuticals Generic industry. This means that BHC’s stock grew similarly to ZTS’s over the last 12 months.

ZTS's P/E Growth Rating (79) in the Pharmaceuticals Generic industry is in the same range as BHC (100) in the Pharmaceuticals Other industry. This means that ZTS’s stock grew similarly to BHC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BHCZTS
RSI
ODDS (%)
Bearish Trend 1 day ago
71%
Bullish Trend 1 day ago
56%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
78%
Bullish Trend 1 day ago
59%
Momentum
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
59%
MACD
ODDS (%)
Bearish Trend 1 day ago
73%
Bearish Trend 1 day ago
61%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
77%
Bearish Trend 1 day ago
57%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
75%
Bearish Trend 1 day ago
59%
Advances
ODDS (%)
Bullish Trend 8 days ago
74%
Bullish Trend 9 days ago
57%
Declines
ODDS (%)
Bearish Trend 1 day ago
77%
Bearish Trend 1 day ago
56%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
72%
Bullish Trend 1 day ago
63%
Aroon
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
61%
View a ticker or compare two or three
Interact to see
Advertisement
BHC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GEMCX21.71N/A
N/A
Goldman Sachs Emerging Markets Eq C
NBHIX14.72N/A
N/A
Neuberger Berman Equity Income I
JABCX48.65N/A
N/A
Janus Henderson Balanced C
VCESX16.40N/A
N/A
Virtus KAR Emerging Markets Small-Cap C
IAFMX19.82N/A
N/A
F/m Investments Large Cap Focused Inv

BHC and

Correlation & Price change

A.I.dvisor tells us that BHC and ELAN have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BHC and ELAN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BHC
1D Price
Change %
BHC100%
-7.82%
ELAN - BHC
27%
Poorly correlated
-3.12%
ZTS - BHC
27%
Poorly correlated
-2.03%
AMPH - BHC
26%
Poorly correlated
-3.28%
TEVA - BHC
25%
Poorly correlated
-8.20%
ESPR - BHC
25%
Poorly correlated
+1.06%
More

ZTS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZTS has been loosely correlated with ELAN. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ZTS jumps, then ELAN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZTS
1D Price
Change %
ZTS100%
-2.03%
ELAN - ZTS
48%
Loosely correlated
-3.12%
VTRS - ZTS
44%
Loosely correlated
-2.94%
PAHC - ZTS
41%
Loosely correlated
-5.09%
AMRX - ZTS
39%
Loosely correlated
-3.10%
HLN - ZTS
36%
Loosely correlated
-3.87%
More